MRNS - マリナス・ファ―マシュ―ティカルズ （Marinus Pharmaceuticals Inc.）

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it. The month of March saw several approvals coming through, while outright rejection and postponements were few and far between. Three new molecular entities, or NMEs, were approved during the month. NMEs are drugs that contain active moieties that haven''t been previously approved by the FDA. It''s, therefore, an indicator of innovation in drug research. Marinus Pharmaceuticals, Inc.''s (NASDAQ: MRNS ) Ztalmy, indicated to treat seizures associated with a rare genetic condition known as CDKL-5 deficiency disorder (CDD), was among the NMEs that scored win the FDA in March. H.C. Wainwright analyst Douglas Tsao expects peak U.S. sales potential of $92 million for Ztalmy, given CDD is a relatively small market. Other NMEs approved during the month included Bristol-Myers Squibb Company''s (NYSE: BMY ) melanoma combo therapy Opdualag and Novartis AG''s (NYSE: NVS ) Pluvicto for treating a certain type of advanced, castration-resistant prostate cancer.

Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals <> to $50 from $35 and maintains a Buy rating on the shares

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it. The month of March saw several approvals coming through, while outright rejection and postponements were few and far between. Three new molecular entities, or NMEs, were approved during the month. NMEs are drugs that contain active moieties that haven''t been previously approved by the FDA. It''s, therefore, an indicator of innovation in drug research. Marinus Pharmaceuticals, Inc.''s (NASDAQ: MRNS ) Ztalmy, indicated to treat seizures associated with a rare genetic condition known as CDKL-5 deficiency disorder (CDD), was among the NMEs that scored win the FDA in March. H.C. Wainwright analyst Douglas Tsao expects peak U.S. sales potential of $92 million for Ztalmy, given CDD is a relatively small market. Other NMEs approved during the month included Bristol-Myers Squibb Company''s (NYSE: BMY ) melanoma combo therapy Opdualag and Novartis AG''s (NYSE: NVS ) Pluvicto for treating a certain type of advanced, castration-resistant prostate cancer.

Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals <> to $50 from $35 and maintains a Buy rating on the shares

Marinus Pharmaceuticals Inc''s (NASDAQ: MRNS ) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short , which is 3.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of … Full story available on Benzinga.com

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

California State Teachers Retirement System increased its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 15.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,899 shares of the biopharmaceutical company’s stock after purchasing an additional 6,962 shares during the period. […]

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts at SVB Leerink upped their FY2021 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a research note issued to investors on Tuesday, November 9th. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($2.75) per share for the year, up from their []

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Research analysts at SVB Leerink increased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a note issued to investors on Tuesday, November 9th. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will earn $1.25 per share for the year, up from their previous []